BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Syneron Candela acquires Ellipse

06 September 2018 | News

Acquisition of Danish Ellipse adds globally renowned IPL and laser technologies to Syneron Candela's portfolio, further strengthening their position in multi-application, multi-technology devices



Syneron Candela, a leading global aesthetic device company, announces the acquisition of Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed.

"The acquisition of Ellipse allows Syneron Candela to strengthen its footprint in the multi-application space and provide our customers a comprehensive portfolio. Syneron Candela's best-in-class laser and energy-based technologies are now coupled with a trusted IPL technology that is well respected by physicians," states Geoffrey Crouse, Chief Executive Officer of Syneron Candela.

"Ellipse platforms will provide aesthetic practices with a fully scalable multi-application, multi-technology device. We look forward to Ellipse strengthening our portfolio as we continue to deliver our brand promise of Science, Results, Trust to our physicians and patients worldwide. The Ellipse product portfolio is consistent with our commitment to scientifically proven technologies backed by consistent clinical outcomes."

Ellipse's key products include Nordlys, a multi-application, multi-technology IPL and Nd: YAG platform for vascular and pigmented lesions, as well as hair removal. The Nordlys also offers a fractionated 1550 nm handpiece for skin resurfacing.

Other products include an IPL-only system used for skin rejuvenation, facial veins and hair removal, as well as a fractional non-ablative laser system used for skin resurfacing.

Ellipse's Selective Waveband Technology (SWT®) uniquely utilizes dual filtering on all IPL handpieces to focus on effective wavelengths and selectively deliver precise energy to the targeted area, using sub-millisecond pulses for some applications.

"We are excited to join forces with Syneron Candela and market our strong technology platforms via Syneron Candela's expansive global footprint, along with its commitment to clinical excellence, quality and innovation," says Jacob Kildegaard Larsen, Chief Executive Officer at Ellipse.

"Syneron Candela and Ellipse are both physician acknowledged leaders in their respective categories. Bringing the companies together will herald a new era in device innovation that elevates patient care," concludes Christine Dierickx, M.D, a Luxembourg based dermatologist, specializing in laser surgery and cosmetic dermatology.